ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 117 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $346,546 | -90.0% | 12,117 | -89.3% | 0.00% | -90.0% |
| Q4 2023 | $3,456,545 | +1087.3% | 112,959 | +942.5% | 0.01% | +900.0% |
| Q3 2023 | $291,136 | -69.9% | 10,835 | -71.5% | 0.00% | -66.7% |
| Q1 2023 | $965,835 | -39.2% | 38,025 | -2.9% | 0.00% | -50.0% |
| Q4 2022 | $1,588,127 | +694.1% | 39,155 | +801.8% | 0.01% | +500.0% |
| Q1 2022 | $200,000 | -89.6% | 4,342 | -82.6% | 0.00% | -87.5% |
| Q4 2020 | $1,916,000 | +75.8% | 24,971 | -1.4% | 0.01% | +100.0% |
| Q3 2020 | $1,090,000 | -83.4% | 25,319 | -83.4% | 0.00% | -87.9% |
| Q2 2020 | $6,583,000 | +297.8% | 152,418 | +165.0% | 0.03% | +200.0% |
| Q1 2020 | $1,655,000 | -87.4% | 57,514 | -72.3% | 0.01% | -74.4% |
| Q4 2019 | $13,171,000 | +293.0% | 207,649 | +74.6% | 0.04% | +258.3% |
| Q3 2019 | $3,351,000 | +524.0% | 118,924 | +487.2% | 0.01% | +500.0% |
| Q2 2019 | $537,000 | +66.8% | 20,254 | +20.7% | 0.00% | +100.0% |
| Q3 2018 | $322,000 | +107.7% | 16,785 | +47.5% | 0.00% | 0.0% |
| Q2 2018 | $155,000 | – | 11,377 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ELEMENT CAPITAL MANAGEMENT LLC | 142,649 | $618,000 | 0.25% |
| ING GROEP NV | 808,229 | $3,500,000 | 0.07% |
| A.R.T. Advisors, LLC | 232,470 | $1,006,000 | 0.05% |
| OppenheimerFunds, Inc. | 3,000,000 | $12,990,000 | 0.02% |
| Edge Wealth Management LLC | 10,000 | $43,000 | 0.01% |
| First Allied Advisory Services, Inc. | 61,000 | $264,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 200,000 | $866,000 | 0.01% |
| MILLENNIUM MANAGEMENT LLC | 1,272,138 | $5,508,000 | 0.01% |
| D. E. Shaw & Co., Inc. | 971,768 | $4,208,000 | 0.01% |
| Virtu Financial LLC | 18,008 | $78,000 | 0.00% |